Ocular Therapeutix
OCUL
71 hedge funds and large institutions have $380M invested in Ocular Therapeutix in 2015 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 38 increasing their positions, 6 reducing their positions, and 10 closing their positions.
533% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 6
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
25% more funds holding
Funds holding: 57 → 71 (+14)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
32% less capital invested
Capital invested by funds: $557M → $380M (-$177M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.2M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$30.5M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$28M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$18.8M |
| 5 |
Jennison Associates
New York
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
-$19.8M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
-$17.1M |
| 3 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$16.2M |
| 4 |
BP
Ballentine Partners
Waltham,
Massachusetts
|
-$8.82M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.23M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
76
Spark Investment Management
New York
| – | -$3.67M | -87,500 | Closed |
|
77
Principal Financial Group
Des Moines,
Iowa
| – | -$2.27M | -54,000 | Closed |
|
78
Allianz Asset Management
Munich,
Germany
| – | -$2.23M | -53,045 | Closed |
|
|
CCM
79
Cadian Capital Management
New York
| – | -$1.47M | -35,000 | Closed |
|
|
CIP
80
Convergence Investment Partners
Palm Beach Gardens,
Florida
| – | -$802K | -19,100 | Closed |
|
81
SG Americas Securities
New York
| – | -$104K | -2,471 | Closed |
|
|
TRCT
82
Tower Research Capital (TRC)
New York
| – | -$21K | -509 | Closed |
|
OCUL Hedge Fund Activity: Q2 2015 in Review
71 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q2 2015, worth a combined $380M — down 32% from $557M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new OCUL positions and 10 closed out — a net gain of 14 holders — while 38 added to existing stakes and 6 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $34.2M. The largest seller was Polaris Venture Management Co V, cutting an estimated $19.8M.
- 71 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2015, up from 57 in Q1 2015.
- Funds reported $380M of Ocular Therapeutix stock for Q2 2015, down 32% quarter-over-quarter.
- 24 funds opened new Ocular Therapeutix positions in Q2 2015 and 10 closed out, a net change of +14 holders.
- The largest Ocular Therapeutix buyer in Q2 2015 was Fidelity Investments, an estimated $34.2M added.
- The largest Ocular Therapeutix seller in Q2 2015 was Polaris Venture Management Co V, an estimated $19.8M sold.
Based on aggregated 13F filings for Q2 2015.